Related Experiment Video
Updated: Jan 3, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children
David T Teachey1, David O'Connor2,3
1Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Insights
Intensified treatment protocols have significantly improved outcomes for pediatric T-cell acute lymphoblastic leukemia (T-ALL). Key changes include asparaginase intensification and dexamethasone use, leading to better survival rates.
Area of Science:
- Pediatric Oncology
- Hematology
- Cancer Therapeutics
Background:
- T-cell acute lymphoblastic leukemia (T-ALL) historically presents a poor prognosis.
- Pediatric T-ALL treatment has seen significant progress without novel agents.
Observation:
- Representative cases illustrate advances in T-ALL treatment protocols.
- Key changes include asparaginase intensification, induction dexamethasone, and omitting cranial radiotherapy.
Findings:
- Risk stratification using minimal residual disease measurement is crucial.
- High-risk subtypes like early T-cell precursor ALL require specific treatment strategies.
- Current treatment protocols show discrepancies between cooperative groups, including nelarabine use.
Implications:
- Optimized T-ALL protocols enhance pediatric patient outcomes.
- Further research into risk stratification and subtype-specific treatments is warranted.
- Standardizing treatment protocols can improve T-ALL and T-lymphoblastic lymphoma management.
Abstract:
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that has historically been associated with a very poor prognosis. Nevertheless, despite a lack of incorporation of novel agents, the development of intensified T-ALL-focused protocols has resulted in significant improvements in outcome in children. Through the use of several representative cases, we highlight the key changes that have driven these advances including asparaginase intensification, the use of induction dexamethasone, and the safe omission of cranial radiotherapy. We discuss the results of recent trials to explore key topics including the implementation of risk stratification with minimal residual disease measurement and how to treat high-risk subtypes such as early T-cell precursor ALL. In particular, we address current discrepancies in treatment between different cooperative groups, including the use of nelarabine, and provide rationales for current treatment protocols for both T-ALL and T-lymphoblastic lymphoma.
